Novo Nordisk Sues Lilly Over Weight Loss Ads | Raleigh News

Novo Nordisk is suing Eli Lilly, claiming their Zepbound ads mislead consumers by comparing results to outdated Wegovy data — ignoring the newer, higher-dose version now on the market. The legal showdown also targets Lilly’s diabetes drug comparisons, with Novo arguing the same flawed data is being used. Lilly stands firm, calling their ads truthful and backed by clinical trials, while the battle heats up in the fiercely competitive weight-loss drug arena. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7e8087640154555e